Skip to main content

Advertisement

Table 1 Demographics of the patients, clinical and laboratory data at time of diagnosis of sJIA, and time and dose of anti-IL-1 medication

From: Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis

Patient 1 2 3
Gender m m f
ANA/RF/HLA-B27 neg/neg/neg neg/neg/n.d. neg/neg/neg
Age at diagnosis 14.8 15.8 6.8
ILAR criteria for subtype Fever, typical rash, splenomegaly, pericardial effusion Fever, rash, pericardial/pleural effusion, hepatomegaly Fever, rash, pleural effusion, hepatomegaly splenomegaly
Affected joints Polyarthritis Polyarthritis Elbows, hips, wrists
Leukocyte count 9100/mm3 (4800–10000) 9100/mm3 (4500–12500) 16800/mm3 (4800–10000)
Platelet count 294000/mm3 (150000–450000) 208000/mm3 (154000–386000) 575000/mm3 (150000–450000)
Ferritin 2926 μg/l (30–400) 32722 ng/ml (22–322) 297–1197 μg/l (30–400)
C-reactive protein 7.4 mg/dl (0.2–1.0) 28.54 mg/dl (<0.3) 3.36 mg/dl (0.2–1.0)
Bone marrow biopsy findings Negative MAS -
Start of IL1-treatment, years after diagnosis 0 years 2.2 years 0.3 years
IL-1 agents, initial dose Anakinra 1.3 mg/kg Canakinumab 1.8 mg/kg Anakinra 1.1 mg/kg
  1. normal values in parentheses
  2. neg negative, n.d. not done